etrasimod vs tamuzimod

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Ulcerative Colitis

Shared mechanism: S1P receptor · full Ulcerative Colitis pipeline

etrasimod · Velsipity

Marketed by Pfizer and partners

Approved in Ulcerative ColitisSmall molecule (S1P1,4,5 modulator)
Reliable signal

NCT03945188 · Phase 3 · completed

Randomized 2:1, double-blind, placebo-controlled, adequately powered (n=433) phase 3 trial with a hard clinical/endoscopic composite primary endpoint (clinical remission via modified Mayo score incorporating centrally-read endoscopy), and both co-primary endpoint comparisons reached statistical significance in the favorable direction (p<0.001), satisfying the 'strong' definition.

Next expected readout: June 2027 · NCT07782242 (registry estimate)

Reported efficacy

Percentage of Participants Achieving Clinical Remission at Week 12; Percentage of Participants Achieving Clinical Remission at Week 52: Percentage of Participants Achieving Clinical Remission at Week 12 (At Week 12): Etrasimod 2 mg 27.0% vs Placebo 7.4%; p=<0.001 (Etrasimod 2 mg vs Placebo) (met)

Result source: NCT03945188

tamuzimod

Developed by Eli Lilly and partners

Phase 2 in Ulcerative ColitisSmall molecule (oral S1P1 receptor modulator)
Reliable signal

NCT05156125 · Phase 2 · terminated

This was a randomized, quadruple-blind, placebo-controlled trial in 213 patients using clinical remission on the modified Mayo score, a validated disease-activity measure combining symptoms and endoscopy, as the primary endpoint. Both the 60 mg and 30 mg tamuzimod doses achieved significantly higher remission rates than placebo at week 13.

Reported efficacy

Clinical Remission at 13 Weeks (Day 1 of Induction treatment period to Week 13): Clinical Remission at 13 Weeks (Day 1 of Induction treatment period to Week 13): VTX002 60 mg Once Daily 19/68 (27.9%) | VTX002 30 mg Once Daily 17/71 (23.9%) vs Placebo Once Daily 8/70 (11.4%) (met)

Result source: NCT05156125

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointetrasimodtamuzimod
Clinical remission (induction)27% vs 7.4%+19.6 vs placebo2 mg · wk 12 · n 274NCT03945188
6 other results
  • 24.8% vs 15.2% 2 mg · wk 12 · n 222 · Phase 3 · primary NCT03996369
  • 26.3% vs 0% 2 mg · wk 12 · n 19 · Phase 2 · primary NCT05061446
  • 6.7% vs 0% 1 mg · wk 12 · n 15 · Phase 2 · primary NCT05061446
  • 33% vs 8.1% 2 mg · wk 12 · n 50 · Phase 2 · secondary NCT02447302
  • 16% vs 8.1% 1 mg · wk 12 · n 52 · Phase 2 · secondary NCT02447302
  • 28.3% vs 11.7% wk 12 · n 127 · Phase 2 · secondary NCT04607837
27.9% vs 11.4%+16.5 vs placebo60 mg once daily · wk 13 · n 68NCT05156125
1 other result
  • 23.9% vs 11.4% 30 mg once daily · wk 13 · n 71 · Phase 2 · primary NCT05156125
Clinical remission (maintenance)32.1% vs 6.7%+25.4 vs placebo2 mg · wk 52 · n 274NCT03945188
3 other results
  • 25% vs 7.1% 2 mg · wk 40 · n 28 · Phase 3 · primary NCT04706793
  • 49.1% vs 17.4% 2 mg · wk 52 · n 171 · Phase 3 · secondary NCT03945188
  • 26% vs 18.3% wk 52 · n 127 · Phase 2 · primary NCT04607837
—Not reported
Clinical response (induction)62.4% vs 34.1%+28.3 vs placebo2 mg · wk 12 · n 274NCT03945188
6 other results
  • 62.2% vs 41.1% 2 mg · wk 12 · n 222 · Phase 3 · secondary NCT03996369
  • 50.6% vs 32.5% 2 mg · wk 12 · n 50 · Phase 2 · secondary NCT02447302
  • 43.7% vs 32.5% 1 mg · wk 12 · n 52 · Phase 2 · secondary NCT02447302
  • 55.9% vs 36.7% wk 12 · n 127 · Phase 2 · secondary NCT04607837
  • 52.6% vs 7.1% 2 mg · wk 12 · n 19 · Phase 2 · secondary NCT05061446
  • 33.3% vs 7.1% 1 mg · wk 12 · n 15 · Phase 2 · secondary NCT05061446
—Not reported
Endoscopic improvement (induction)35% vs 14.1%+20.9 vs placebo2 mg · wk 12 · n 274NCT03945188
6 other results
  • 30.6% vs 18.8% 2 mg · wk 12 · n 222 · Phase 3 · secondary NCT03996369
  • 41.8% vs 17.8% 2 mg · wk 12 · n 50 · Phase 2 · secondary NCT02447302
  • 22.5% vs 17.8% 1 mg · wk 12 · n 52 · Phase 2 · secondary NCT02447302
  • 44.1% vs 20% wk 12 · n 127 · Phase 2 · secondary NCT04607837
  • 26.3% vs 0% 2 mg · wk 12 · n 19 · Phase 2 · secondary NCT05061446
  • 6.7% vs 0% 1 mg · wk 12 · n 15 · Phase 2 · secondary NCT05061446
—Not reported
Corticosteroid-free remission (maintenance)32.1% vs 6.7%+25.4 vs placebo2 mg · wk 52 · n 274NCT03945188
6 other results
  • 31% vs 7.5% 2 mg · wk 52 · n 87 · Phase 3 · secondary NCT03945188
  • 25% vs 7.1% 2 mg · wk 40 · n 28 · Phase 3 · secondary NCT04706793
  • 25.2% vs 16.7% wk 52 · n 127 · Phase 2 · secondary NCT04607837
  • 25.2% vs 16.7% wk 52 · n 127 · Phase 2 · secondary NCT04607837
  • 16.2% vs 16.7% wk 52 · n 37 · Phase 2 · secondary NCT04607837
  • 30% vs 30% wk 52 · n 20 · Phase 2 · secondary NCT04607837
—Not reported

Clinical remission (induction)

etrasimod
27% vs 7.4%+19.6 vs placebo2 mg · wk 12 · n 274NCT03945188
6 other results
  • 24.8% vs 15.2% 2 mg · wk 12 · n 222 · Phase 3 · primary NCT03996369
  • 26.3% vs 0% 2 mg · wk 12 · n 19 · Phase 2 · primary NCT05061446
  • 6.7% vs 0% 1 mg · wk 12 · n 15 · Phase 2 · primary NCT05061446
  • 33% vs 8.1% 2 mg · wk 12 · n 50 · Phase 2 · secondary NCT02447302
  • 16% vs 8.1% 1 mg · wk 12 · n 52 · Phase 2 · secondary NCT02447302
  • 28.3% vs 11.7% wk 12 · n 127 · Phase 2 · secondary NCT04607837
tamuzimod
27.9% vs 11.4%+16.5 vs placebo60 mg once daily · wk 13 · n 68NCT05156125
1 other result
  • 23.9% vs 11.4% 30 mg once daily · wk 13 · n 71 · Phase 2 · primary NCT05156125

Clinical remission (maintenance)

etrasimod
32.1% vs 6.7%+25.4 vs placebo2 mg · wk 52 · n 274NCT03945188
3 other results
  • 25% vs 7.1% 2 mg · wk 40 · n 28 · Phase 3 · primary NCT04706793
  • 49.1% vs 17.4% 2 mg · wk 52 · n 171 · Phase 3 · secondary NCT03945188
  • 26% vs 18.3% wk 52 · n 127 · Phase 2 · primary NCT04607837
tamuzimod
—Not reported

Clinical response (induction)

etrasimod
62.4% vs 34.1%+28.3 vs placebo2 mg · wk 12 · n 274NCT03945188
6 other results
  • 62.2% vs 41.1% 2 mg · wk 12 · n 222 · Phase 3 · secondary NCT03996369
  • 50.6% vs 32.5% 2 mg · wk 12 · n 50 · Phase 2 · secondary NCT02447302
  • 43.7% vs 32.5% 1 mg · wk 12 · n 52 · Phase 2 · secondary NCT02447302
  • 55.9% vs 36.7% wk 12 · n 127 · Phase 2 · secondary NCT04607837
  • 52.6% vs 7.1% 2 mg · wk 12 · n 19 · Phase 2 · secondary NCT05061446
  • 33.3% vs 7.1% 1 mg · wk 12 · n 15 · Phase 2 · secondary NCT05061446
tamuzimod
—Not reported

Endoscopic improvement (induction)

etrasimod
35% vs 14.1%+20.9 vs placebo2 mg · wk 12 · n 274NCT03945188
6 other results
  • 30.6% vs 18.8% 2 mg · wk 12 · n 222 · Phase 3 · secondary NCT03996369
  • 41.8% vs 17.8% 2 mg · wk 12 · n 50 · Phase 2 · secondary NCT02447302
  • 22.5% vs 17.8% 1 mg · wk 12 · n 52 · Phase 2 · secondary NCT02447302
  • 44.1% vs 20% wk 12 · n 127 · Phase 2 · secondary NCT04607837
  • 26.3% vs 0% 2 mg · wk 12 · n 19 · Phase 2 · secondary NCT05061446
  • 6.7% vs 0% 1 mg · wk 12 · n 15 · Phase 2 · secondary NCT05061446
tamuzimod
—Not reported

Corticosteroid-free remission (maintenance)

etrasimod
32.1% vs 6.7%+25.4 vs placebo2 mg · wk 52 · n 274NCT03945188
6 other results
  • 31% vs 7.5% 2 mg · wk 52 · n 87 · Phase 3 · secondary NCT03945188
  • 25% vs 7.1% 2 mg · wk 40 · n 28 · Phase 3 · secondary NCT04706793
  • 25.2% vs 16.7% wk 52 · n 127 · Phase 2 · secondary NCT04607837
  • 25.2% vs 16.7% wk 52 · n 127 · Phase 2 · secondary NCT04607837
  • 16.2% vs 16.7% wk 52 · n 37 · Phase 2 · secondary NCT04607837
  • 30% vs 30% wk 52 · n 20 · Phase 2 · secondary NCT04607837
tamuzimod
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. etrasimod: 5 of 5 rows · tamuzimod: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricetrasimodtamuzimod
Symptomatic Remission
responder rate · % of participants
Induction
43.1% (n=274) vs 21.5% (n=135) placebo @ 16wk2 mga,b,c
NCT03945188 · Phase 3 · monotherapy
42.6% (n=68) vs 25.7% (n=70) placebo @ 13wk*60 mg once dailyd,a,b,c
NCT05156125 · Phase 2 · monotherapy · converted to % from 29 Participants as posted
show 1 more dose
40.8% (n=71) vs 25.7% (n=70) placebo @ 13wk*30 mg once daily
NCT05156125 · Phase 2 · monotherapy · converted to % from 29 Participants as posted
Dropout rate
44.3%2 mge
NCT03945188 · Phase 3 · monotherapy
show 8 more results
10.5%2 mg
NCT03996369 · Phase 3 · monotherapy
35.7%2 mg
NCT04706793 · Phase 3 · monotherapy
37.4%
NCT04607837 · Phase 2 · registry result, not featured evidence
0%2 mg
NCT05061446 · Phase 2 · registry result, not featured evidence
5.9%1 mg
NCT05061446 · Phase 2 · registry result, not featured evidence
17.9%2 mg
NCT02536404 · Phase 2 · registry result, not featured evidence
8%2 mg
NCT02447302 · Phase 2 · registry result, not featured evidence
9.6%1 mg
NCT02447302 · Phase 2 · registry result, not featured evidence
4.3%60 mg once dailye
NCT05156125 · Phase 2 · monotherapy
show 6 more results
—60 mg once daily
NCT05156125 · Phase 2 · monotherapy
—60 mg once daily
NCT05156125 · Phase 2 · monotherapy
—60 mg once daily
NCT05156125 · Phase 2 · monotherapy
4.1%30 mg once daily
NCT05156125 · Phase 2 · monotherapy
—30 mg once daily
NCT05156125 · Phase 2 · monotherapy
—30 mg once daily
NCT05156125 · Phase 2 · monotherapy
Discontinued due to AEs
3.5%2 mge
NCT03945188 · Phase 3 · monotherapy
show 8 more results
3.8%2 mg
NCT03996369 · Phase 3 · monotherapy
—2 mg
NCT04706793 · Phase 3 · monotherapy
5.2%
NCT04607837 · Phase 2 · registry result, not featured evidence
0%2 mg
NCT05061446 · Phase 2 · registry result, not featured evidence
0%1 mg
NCT05061446 · Phase 2 · registry result, not featured evidence
4.5%2 mg
NCT02536404 · Phase 2 · registry result, not featured evidence
6%2 mg
NCT02447302 · Phase 2 · registry result, not featured evidence
7.7%1 mg
NCT02447302 · Phase 2 · registry result, not featured evidence
2.9%60 mg once dailye
NCT05156125 · Phase 2 · monotherapy
show 6 more results
—60 mg once daily
NCT05156125 · Phase 2 · monotherapy
—60 mg once daily
NCT05156125 · Phase 2 · monotherapy
—60 mg once daily
NCT05156125 · Phase 2 · monotherapy
1.4%30 mg once daily
NCT05156125 · Phase 2 · monotherapy
—30 mg once daily
NCT05156125 · Phase 2 · monotherapy
—30 mg once daily
NCT05156125 · Phase 2 · monotherapy
Serious AEs
6.9%2 mge
NCT03945188 · Phase 3 · monotherapy
show 8 more results
2.5%2 mg
NCT03996369 · Phase 3 · monotherapy
3.6%2 mg
NCT04706793 · Phase 3 · monotherapy
6.5%
NCT04607837 · Phase 2 · registry result, not featured evidence
0%2 mg
NCT05061446 · Phase 2 · registry result, not featured evidence
0%1 mg
NCT05061446 · Phase 2 · registry result, not featured evidence
6.3%2 mg
NCT02536404 · Phase 2 · registry result, not featured evidence
0%2 mg
NCT02447302 · Phase 2 · registry result, not featured evidence
5.8%1 mg
NCT02447302 · Phase 2 · registry result, not featured evidence
—60 mg once dailye
NCT05156125 · Phase 2 · monotherapy
show 6 more results
4.3%60 mg once daily
NCT05156125 · Phase 2 · monotherapy
0%60 mg once daily
NCT05156125 · Phase 2 · monotherapy
4.2%60 mg once daily
NCT05156125 · Phase 2 · monotherapy
—30 mg once daily
NCT05156125 · Phase 2 · monotherapy
2.7%30 mg once daily
NCT05156125 · Phase 2 · monotherapy
5.4%30 mg once daily
NCT05156125 · Phase 2 · monotherapy
Most frequent reported AEs
2 mge
anaemia 8.3% (placebo 9.7%)
headache 8.3% (placebo 4.9%)
covid-19 6.6% (placebo 5.6%)
NCT03945188 · Phase 3 · monotherapy
show 8 more results
2 mg
anaemia 5.9% (placebo 6.9%)
headache 4.6% (placebo 1.7%)
nausea 4.2% (placebo 1.7%)
NCT03996369 · Phase 3 · monotherapy
2 mg
headache 14.3% (placebo 14.3%)
malaise 10.7% (placebo 0%)
pyrexia 10.7% (placebo 14.3%)
NCT04706793 · Phase 3 · monotherapy
colitis ulcerative 12.3% (placebo 10.1%)
covid-19 9.7% (placebo 8.9%)
alanine aminotransferase increased 8.4% (placebo 1.3%)
NCT04607837 · Phase 2 · registry result, not featured evidence
2 mg
alanine aminotransferase increased 5.3% (placebo 0%)
back pain 5.3% (placebo 0%)
blood creatine phosphokinase increased 5.3% (placebo 0%)
NCT05061446 · Phase 2 · registry result, not featured evidence
1 mg
stomatitis 11.8% (placebo 0%)
anaemia 5.9% (placebo 0%)
cataract 5.9% (placebo 0%)
NCT05061446 · Phase 2 · registry result, not featured evidence
2 mg
colitis ulcerative 14.3% (placebo 16.7%)
anaemia 8.9% (placebo 0%)
gamma-glutamyltransferase increased 8.9% (placebo 0%)
NCT02536404 · Phase 2 · registry result, not featured evidence
2 mg
anaemia 6% (placebo 3.7%)
headache 6% (placebo 1.9%)
colitis ulcerative 4% (placebo 1.9%)
NCT02447302 · Phase 2 · registry result, not featured evidence
1 mg
upper respiratory tract infection 7.7% (placebo 3.7%)
colitis ulcerative 5.8% (placebo 1.9%)
anaemia 3.8% (placebo 3.7%)
NCT02447302 · Phase 2 · registry result, not featured evidence
60 mg once dailye
upper respiratory tract infection 8.6% (placebo 1.4%)
headache 5.7% (placebo 2.9%)
anaemia 2.9% (placebo 8.6%)
NCT05156125 · Phase 2 · monotherapy
show 4 more results
60 mg once daily
alanine aminotransferase increased 6.1% (placebo 1.4%)
aspartate animotransferase increased 6.1% (placebo 0%)
gamma-glutamyltransferase increased 6.1% (placebo 1.4%)
NCT05156125 · Phase 2 · monotherapy
60 mg once daily
lymphopenia 28.9% (placebo 0%)
nasopharyngitis 7.4% (placebo 4.3%)
upper respiratory tract infection 6.3% (placebo 1.4%)
NCT05156125 · Phase 2 · monotherapy
30 mg once daily
headache 6.8% (placebo 2.9%)
anaemia 5.5% (placebo 8.6%)
lymphopenia 1.4% (placebo 0%)
NCT05156125 · Phase 2 · monotherapy
30 mg once daily
gamma-glutamyltransferase increased 10.8% (placebo 1.4%)
alanine aminotransferase increased 5.4% (placebo 1.4%)
arthralgia 5.4% (placebo 0%)
NCT05156125 · Phase 2 · monotherapy

Notes

  1. aTrial phases differ: Phase 3 versus Phase 2.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cAssessment timepoints differ: 16 weeks versus 13 weeks.
  4. dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  5. ePopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

etrasimod

Endoscopic Improvement 35% (n=274) vs 14.1% (n=135) placebo @ 12wk2 mg
responder rate · % of participants
NCT03945188 · Phase 3 · monotherapy
show 9 more results
37.2% (n=274) vs 10.4% (n=135) placebo @ 52wk2 mg
NCT03945188 · Phase 3 · monotherapy
30.6% (n=222) vs 18.8% (n=112) placebo @ 12wk2 mg
NCT03996369 · Phase 3 · monotherapy
35.7% (n=28) vs 7.1% (n=14) placebo @ 40wk2 mg
NCT04706793 · Phase 3 · monotherapy
26.3% (n=19) vs 0% (n=14) placebo @ 12wk2 mg
NCT05061446 · Phase 2 · registry result, not featured evidence
41.8% (n=50) vs 17.8% (n=54) placebo @ 12wk2 mg
NCT02447302 · Phase 2 · registry result, not featured evidence
6.7% (n=15) vs 0% (n=14) placebo @ 12wk1 mg
NCT05061446 · Phase 2 · registry result, not featured evidence
22.5% (n=52) vs 17.8% (n=54) placebo @ 12wk1 mg
NCT02447302 · Phase 2 · registry result, not featured evidence
32.3% (n=127) vs 23.3% (n=60) placebo @ 52wk
NCT04607837 · Phase 2 · registry result, not featured evidence
44.1% (n=127) vs 20% (n=60) placebo @ 12wk
NCT04607837 · Phase 2 · registry result, not featured evidence
Mucosal Healing 21.2% (n=274) vs 4.4% (n=135) placebo @ 12wk2 mg
responder rate · % of participants
NCT03945188 · Phase 3 · monotherapy
show 5 more results
26.6% (n=274) vs 8.1% (n=135) placebo @ 52wk2 mg
NCT03945188 · Phase 3 · monotherapy
16.2% (n=222) vs 8.9% (n=112) placebo @ 12wk2 mg
NCT03996369 · Phase 3 · monotherapy
28.6% (n=28) vs 7.1% (n=14) placebo @ 40wk2 mg
NCT04706793 · Phase 3 · monotherapy
5.3% (n=19) vs 0% (n=14) placebo @ 12wk2 mg
NCT05061446 · Phase 2 · registry result, not featured evidence
6.7% (n=15) vs 0% (n=14) placebo @ 12wk1 mg
NCT05061446 · Phase 2 · registry result, not featured evidence
Corticosteroid-free Clinical Remission 32.1% (n=274) vs 6.7% (n=135) placebo @ 52wk2 mg
responder rate · % of participants
NCT03945188 · Phase 3 · monotherapy
show 6 more results
31% (n=87) vs 7.5% (n=40) placebo @ 52wk2 mg
NCT03945188 · Phase 3 · monotherapy
25% (n=28) vs 7.1% (n=14) placebo @ 40wk2 mg
NCT04706793 · Phase 3 · monotherapy
16.2% (n=37) vs 16.7% (n=18) placebo @ 52wk
NCT04607837 · Phase 2 · registry result, not featured evidence
25.2% (n=127) vs 16.7% (n=60) placebo @ 52wk
NCT04607837 · Phase 2 · registry result, not featured evidence
30% (n=20) vs 30% (n=10) placebo @ 52wk
NCT04607837 · Phase 2 · registry result, not featured evidence
25.2% (n=127) vs 16.7% (n=60) placebo @ 52wk
NCT04607837 · Phase 2 · registry result, not featured evidence
Sustained Clinical Remission 17.9% (n=274) vs 2.2% (n=135) placebo2 mg
responder rate · % of participants
NCT03945188 · Phase 3 · monotherapy
show 2 more results
7.1% (n=28) vs 0% (n=14) placebo @ 40wk2 mg
NCT04706793 · Phase 3 · monotherapy
16.5% (n=127) vs 5% (n=60) placebo
NCT04607837 · Phase 2 · registry result, not featured evidence
Clinical Response 62.4% (n=274) vs 34.1% (n=135) placebo @ 12wk2 mg
responder rate · % of participants
NCT03945188 · Phase 3 · monotherapy
show 8 more results
48.2% (n=274) vs 23% (n=135) placebo @ 52wk2 mg
NCT03945188 · Phase 3 · monotherapy
62.2% (n=222) vs 41.1% (n=112) placebo @ 12wk2 mg
NCT03996369 · Phase 3 · monotherapy
52.6% (n=19) vs 7.1% (n=14) placebo @ 12wk2 mg
NCT05061446 · Phase 2 · registry result, not featured evidence
50.6% (n=50) vs 32.5% (n=54) placebo @ 12wk2 mg
NCT02447302 · Phase 2 · registry result, not featured evidence
33.3% (n=15) vs 7.1% (n=14) placebo @ 12wk1 mg
NCT05061446 · Phase 2 · registry result, not featured evidence
43.7% (n=52) vs 32.5% (n=54) placebo @ 12wk1 mg
NCT02447302 · Phase 2 · registry result, not featured evidence
55.9% (n=127) vs 36.7% (n=60) placebo @ 12wk
NCT04607837 · Phase 2 · registry result, not featured evidence
44.1% (n=127) vs 38.3% (n=60) placebo @ 52wk
NCT04607837 · Phase 2 · registry result, not featured evidence
Sustained Clinical 44.9% (n=274) vs 18.5% (n=135) placebo2 mg
responder rate · % of participants
NCT03945188 · Phase 3 · monotherapy
Sustained Mucosal Healing 13.5% (n=274) vs 2.2% (n=135) placebo2 mg
responder rate · % of participants
NCT03945188 · Phase 3 · monotherapy
Endoscopic Normalization 14.6% (n=274) vs 4.4% (n=135) placebo @ 12wk2 mg
responder rate · % of participants
NCT03945188 · Phase 3 · monotherapy
show 4 more results
26.3% (n=274) vs 5.9% (n=135) placebo @ 52wk2 mg
NCT03945188 · Phase 3 · monotherapy
17.1% (n=222) vs 8% (n=112) placebo @ 12wk2 mg
NCT03996369 · Phase 3 · monotherapy
0% (n=19) vs 0% (n=14) placebo @ 12wk2 mg
NCT05061446 · Phase 2 · registry result, not featured evidence
0% (n=15) vs 0% (n=14) placebo @ 12wk1 mg
NCT05061446 · Phase 2 · registry result, not featured evidence
Sustained Endoscopic Normalization 10.6% (n=274) vs 1.5% (n=135) placebo2 mg
responder rate · % of participants
NCT03945188 · Phase 3 · monotherapy
Complete Symptomatic Remission 5.8% (n=274) vs 2.2% (n=135) placebo @ 2wk2 mg
responder rate · % of participants
NCT03945188 · Phase 3 · monotherapy
show 16 more results
11.3% (n=274) vs 4.4% (n=135) placebo @ 4wk2 mg
NCT03945188 · Phase 3 · monotherapy
16.8% (n=274) vs 6.7% (n=135) placebo @ 8wk2 mg
NCT03945188 · Phase 3 · monotherapy
23% (n=274) vs 6.7% (n=135) placebo @ 12wk2 mg
NCT03945188 · Phase 3 · monotherapy
21.2% (n=274) vs 5.9% (n=135) placebo @ 16wk2 mg
NCT03945188 · Phase 3 · monotherapy
22.3% (n=274) vs 4.4% (n=135) placebo @ 20wk2 mg
NCT03945188 · Phase 3 · monotherapy
22.3% (n=274) vs 8.1% (n=135) placebo @ 24wk2 mg
NCT03945188 · Phase 3 · monotherapy
23% (n=274) vs 3% (n=135) placebo @ 32wk2 mg
NCT03945188 · Phase 3 · monotherapy
21.2% (n=274) vs 5.9% (n=135) placebo @ 40wk2 mg
NCT03945188 · Phase 3 · monotherapy
19.7% (n=274) vs 2.2% (n=135) placebo @ 48wk2 mg
NCT03945188 · Phase 3 · monotherapy
24.5% (n=274) vs 4.4% (n=135) placebo @ 52wk2 mg
NCT03945188 · Phase 3 · monotherapy
4.5% (n=222) vs 1.8% (n=112) placebo @ 2wk2 mg
NCT03996369 · Phase 3 · monotherapy
11.7% (n=222) vs 3.6% (n=112) placebo @ 4wk2 mg
NCT03996369 · Phase 3 · monotherapy
14% (n=222) vs 7.1% (n=112) placebo @ 8wk2 mg
NCT03996369 · Phase 3 · monotherapy
18% (n=222) vs 8.9% (n=112) placebo @ 12wk2 mg
NCT03996369 · Phase 3 · monotherapy
20.5% (n=127) vs 20% (n=60) placebo @ 52wk
NCT04607837 · Phase 2 · registry result, not featured evidence
20.5% (n=127) vs 20% (n=60) placebo @ 12wk
NCT04607837 · Phase 2 · registry result, not featured evidence
Non-invasive Clinical 38.3% (n=274) vs 33.3% (n=135) placebo @ 2wk2 mg
responder rate · % of participants
NCT03945188 · Phase 3 · monotherapy
show 10 more results
56.2% (n=274) vs 39.3% (n=135) placebo @ 4wk2 mg
NCT03945188 · Phase 3 · monotherapy
63.1% (n=274) vs 43% (n=135) placebo @ 8wk2 mg
NCT03945188 · Phase 3 · monotherapy
65.7% (n=274) vs 42.2% (n=135) placebo @ 12wk2 mg
NCT03945188 · Phase 3 · monotherapy
55.5% (n=274) vs 30.4% (n=135) placebo @ 16wk2 mg
NCT03945188 · Phase 3 · monotherapy
57.3% (n=274) vs 28.1% (n=135) placebo @ 20wk2 mg
NCT03945188 · Phase 3 · monotherapy
56.6% (n=274) vs 30.4% (n=135) placebo @ 24wk2 mg
NCT03945188 · Phase 3 · monotherapy
54% (n=274) vs 25.2% (n=135) placebo @ 32wk2 mg
NCT03945188 · Phase 3 · monotherapy
51.5% (n=274) vs 23% (n=135) placebo @ 40wk2 mg
NCT03945188 · Phase 3 · monotherapy
51.1% (n=274) vs 21.5% (n=135) placebo @ 48wk2 mg
NCT03945188 · Phase 3 · monotherapy
50.4% (n=274) vs 23.7% (n=135) placebo @ 52wk2 mg
NCT03945188 · Phase 3 · monotherapy
Symptomatic 39.4% (n=274) vs 33.3% (n=135) placebo @ 2wk2 mg
responder rate · % of participants
NCT03945188 · Phase 3 · monotherapy
show 14 more results
57.3% (n=274) vs 40% (n=135) placebo @ 4wk2 mg
NCT03945188 · Phase 3 · monotherapy
64.6% (n=274) vs 43.7% (n=135) placebo @ 8wk2 mg
NCT03945188 · Phase 3 · monotherapy
66.4% (n=274) vs 42.2% (n=135) placebo @ 12wk2 mg
NCT03945188 · Phase 3 · monotherapy
55.5% (n=274) vs 31.1% (n=135) placebo @ 16wk2 mg
NCT03945188 · Phase 3 · monotherapy
57.7% (n=274) vs 28.1% (n=135) placebo @ 20wk2 mg
NCT03945188 · Phase 3 · monotherapy
56.9% (n=274) vs 30.4% (n=135) placebo @ 24wk2 mg
NCT03945188 · Phase 3 · monotherapy
54.7% (n=274) vs 25.2% (n=135) placebo @ 32wk2 mg
NCT03945188 · Phase 3 · monotherapy
51.8% (n=274) vs 23% (n=135) placebo @ 40wk2 mg
NCT03945188 · Phase 3 · monotherapy
51.5% (n=274) vs 21.5% (n=135) placebo @ 48wk2 mg
NCT03945188 · Phase 3 · monotherapy
50.7% (n=274) vs 23.7% (n=135) placebo @ 52wk2 mg
NCT03945188 · Phase 3 · monotherapy
39.6% (n=222) vs 24.1% (n=112) placebo @ 2wk2 mg
NCT03996369 · Phase 3 · monotherapy
56.3% (n=222) vs 41.1% (n=112) placebo @ 4wk2 mg
NCT03996369 · Phase 3 · monotherapy
68.5% (n=222) vs 46.4% (n=112) placebo @ 8wk2 mg
NCT03996369 · Phase 3 · monotherapy
68.5% (n=222) vs 50% (n=112) placebo @ 12wk2 mg
NCT03996369 · Phase 3 · monotherapy

+ 9 further endpoints in the CSV export.

tamuzimod

Endoscopic Improvement 36.8% (n=68) vs 15.7% (n=70) placebo @ 13wk60 mg once daily
event count · % of participants
NCT05156125 · Phase 2 · monotherapy · converted to % from 25 Participants as posted
show 1 more result
32.4% (n=71) vs 15.7% (n=70) placebo @ 13wk*30 mg once daily
NCT05156125 · Phase 2 · monotherapy · converted to % from 23 Participants as posted
Histologic Remission 19.1% (n=68) vs 7.1% (n=70) placebo @ 13wk60 mg once daily
responder rate · % of participants
NCT05156125 · Phase 2 · monotherapy · converted to % from 13 Participants as posted
show 1 more result
28.2% (n=71) vs 7.1% (n=70) placebo @ 13wk*30 mg once daily
NCT05156125 · Phase 2 · monotherapy · converted to % from 20 Participants as posted
Endoscopic Improvement-Histologic Remission 10.3% (n=68) vs 0% (n=70) placebo @ 13wk60 mg once daily
responder rate · % of participants
NCT05156125 · Phase 2 · monotherapy · converted to % from 7 Participants as posted
show 1 more result
19.7% (n=71) vs 0% (n=70) placebo @ 13wk*30 mg once daily
NCT05156125 · Phase 2 · monotherapy · converted to % from 14 Participants as posted

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: etrasimod's landscape · tamuzimod's landscape